SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 134 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $457,780 | -54.7% | 763,220 | -1.8% | 0.00% | – |
| Q2 2023 | $1,010,277 | -63.8% | 777,136 | -51.0% | 0.00% | – |
| Q1 2023 | $2,791,240 | -16.2% | 1,585,932 | +49.5% | 0.00% | – |
| Q4 2022 | $3,332,078 | -37.9% | 1,061,171 | -3.0% | 0.00% | -100.0% |
| Q3 2022 | $5,363,000 | -8.4% | 1,094,249 | -22.6% | 0.00% | 0.0% |
| Q2 2022 | $5,856,000 | +17.3% | 1,414,525 | +64.7% | 0.00% | 0.0% |
| Q1 2022 | $4,991,000 | -48.4% | 858,965 | -33.4% | 0.00% | 0.0% |
| Q4 2021 | $9,673,000 | +6.8% | 1,289,584 | +28.2% | 0.00% | 0.0% |
| Q3 2021 | $9,061,000 | -15.1% | 1,005,755 | +12.9% | 0.00% | 0.0% |
| Q2 2021 | $10,667,000 | +19.2% | 891,147 | +24.7% | 0.00% | 0.0% |
| Q1 2021 | $8,951,000 | -29.6% | 714,372 | -12.4% | 0.00% | -50.0% |
| Q4 2020 | $12,722,000 | +300.8% | 815,255 | +142.7% | 0.00% | +100.0% |
| Q3 2020 | $3,174,000 | -11.4% | 335,848 | -16.0% | 0.00% | 0.0% |
| Q2 2020 | $3,584,000 | +42.3% | 399,947 | +1.2% | 0.00% | 0.0% |
| Q1 2020 | $2,518,000 | -63.1% | 395,329 | -51.5% | 0.00% | -50.0% |
| Q4 2019 | $6,820,000 | -5.6% | 814,691 | +2.1% | 0.00% | 0.0% |
| Q3 2019 | $7,224,000 | +58.5% | 798,236 | +88.6% | 0.00% | +100.0% |
| Q2 2019 | $4,558,000 | -10.0% | 423,301 | -20.3% | 0.00% | 0.0% |
| Q1 2019 | $5,065,000 | -20.7% | 530,968 | -4.6% | 0.00% | -50.0% |
| Q4 2018 | $6,387,000 | -36.4% | 556,425 | -6.1% | 0.00% | -33.3% |
| Q3 2018 | $10,049,000 | -22.7% | 592,793 | -35.2% | 0.00% | -25.0% |
| Q2 2018 | $12,996,000 | -44.9% | 915,183 | -26.2% | 0.00% | -42.9% |
| Q1 2018 | $23,574,000 | +240.3% | 1,240,739 | +193.7% | 0.01% | +250.0% |
| Q4 2017 | $6,928,000 | -34.5% | 422,397 | -40.1% | 0.00% | -33.3% |
| Q3 2017 | $10,577,000 | +202.8% | 705,124 | +77.6% | 0.00% | +200.0% |
| Q2 2017 | $3,493,000 | +8.8% | 396,976 | -35.7% | 0.00% | – |
| Q1 2017 | $3,210,000 | +27.0% | 617,410 | -25.5% | 0.00% | – |
| Q4 2016 | $2,528,000 | +64.2% | 829,100 | +149.3% | 0.00% | -100.0% |
| Q3 2016 | $1,540,000 | -15.0% | 332,634 | +6.3% | 0.00% | 0.0% |
| Q2 2016 | $1,812,000 | -8.7% | 312,911 | -4.6% | 0.00% | 0.0% |
| Q1 2016 | $1,984,000 | -37.1% | 327,993 | -5.0% | 0.00% | 0.0% |
| Q4 2015 | $3,152,000 | +40.8% | 345,344 | -13.0% | 0.00% | 0.0% |
| Q3 2015 | $2,239,000 | -49.5% | 396,869 | -0.7% | 0.00% | -50.0% |
| Q2 2015 | $4,433,000 | -34.6% | 399,704 | -7.6% | 0.00% | 0.0% |
| Q1 2015 | $6,781,000 | +0.5% | 432,484 | -2.5% | 0.00% | 0.0% |
| Q4 2014 | $6,746,000 | +28.9% | 443,554 | -8.6% | 0.00% | 0.0% |
| Q3 2014 | $5,232,000 | -24.1% | 485,113 | +7.4% | 0.00% | -33.3% |
| Q2 2014 | $6,895,000 | -21.4% | 451,569 | -6.9% | 0.00% | -25.0% |
| Q1 2014 | $8,774,000 | +52.4% | 485,275 | +17.1% | 0.00% | +100.0% |
| Q4 2013 | $5,756,000 | +36.2% | 414,363 | +2.8% | 0.00% | 0.0% |
| Q3 2013 | $4,225,000 | -9.7% | 402,917 | -32.8% | 0.00% | 0.0% |
| Q2 2013 | $4,681,000 | – | 599,379 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |